Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has provided an update.
Fusen Pharmaceutical Company Limited has announced a change of auditor, with KPMG resigning effective 24 December 2025 after the two sides failed to agree on the audit fee for the Group’s 2025 consolidated financial statements. The board and audit committee stated there were no other disagreements or matters requiring shareholder attention and expect no material impact on the annual audit or the release of 2025 results. Following a review of audit proposals, experience, resources, independence and market reputation in line with guidelines from Hong Kong’s Accounting and Financial Reporting Council, the audit committee recommended and the board approved the appointment of CCTH CPA Limited as the new auditor until the next annual general meeting. Management said the change is intended to support cost control and reduce overall operating expenses, positioning the Group to better manage future business development while maintaining audit quality, which they view as being in the interests of the company and its shareholders.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited is a Cayman Islands–incorporated pharmaceutical group listed in Hong Kong, engaged in the development, manufacturing and sale of pharmaceutical products, with its operations conducted through its subsidiaries.
Average Trading Volume: 1,064,343
Technical Sentiment Signal: Buy
Current Market Cap: HK$551.4M
Find detailed analytics on 1652 stock on TipRanks’ Stock Analysis page.